S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report.
2021
S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
0
Citations
NaN
KQI